Photon IMRT treatment group displays no significant survival difference between arms

(NRG Oncology) A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news